目的:系统评价局部应用前列腺素类似物滴眼液对原发性开角型青光眼患者角膜厚度的影响,为临床用药提供循证参考。方法:计算机检索Cochrane图书馆、PubMed、Embase、Medline、中国知网、维普数据库、中国生物医学文献数据库和万方数据库...目的:系统评价局部应用前列腺素类似物滴眼液对原发性开角型青光眼患者角膜厚度的影响,为临床用药提供循证参考。方法:计算机检索Cochrane图书馆、PubMed、Embase、Medline、中国知网、维普数据库、中国生物医学文献数据库和万方数据库等,收集前列腺素类似物滴眼液(试验组)对比常规治疗药物或安慰剂(对照组)对原发性开角型青光眼患者角膜厚度影响的随机对照试验(RCT),提取资料并按Cochrane系统评价员手册5.2中的工具评价文献质量后,采用Rev Man 5.3统计软件进行Meta分析。结果:共纳入6项RCT,合计527例患者。Meta分析结果显示,两组患者中央角膜厚度[MD=-13.63,95%CI(-28.50,1.23),P=0.07]、顶端角膜厚度[MD=-7.53,95%CI(-19.46,4.40),P=0.22]、最薄角膜厚度[MD=-5.87,95%CI(-17.69,5.95),P=0.33]、眼压[MD=-5.44,95%CI(-14.90,4.02),P=0.26]比较,差异均无统计学意义。结论:前列腺素类似物滴眼液对原发性开角型青光眼患者的角膜厚度无显著影响。展开更多
The phenyl-substituted analog of prostaglandin F2α , latanoprost ( Xalatan; Pfizer, Inc, New York, NY) is an intraocular pressure (IOP)-lowering drug for use in patients with glaucoma and ocular hypertension. Latanop...The phenyl-substituted analog of prostaglandin F2α , latanoprost ( Xalatan; Pfizer, Inc, New York, NY) is an intraocular pressure (IOP)-lowering drug for use in patients with glaucoma and ocular hypertension. Latanoprost has been sho wn to stimulate eyelash hypertrichosis and has recently been proposed as a possi ble treatment for alopecia areata involving the eyelashes. We report a case of h ypertrichosis of the eyelashes caused by the prostamide bimatoprost (Lumigan; Al lergan, Inc, Irvine, Calif), a new IOP-lowering drug.展开更多
文摘目的:系统评价局部应用前列腺素类似物滴眼液对原发性开角型青光眼患者角膜厚度的影响,为临床用药提供循证参考。方法:计算机检索Cochrane图书馆、PubMed、Embase、Medline、中国知网、维普数据库、中国生物医学文献数据库和万方数据库等,收集前列腺素类似物滴眼液(试验组)对比常规治疗药物或安慰剂(对照组)对原发性开角型青光眼患者角膜厚度影响的随机对照试验(RCT),提取资料并按Cochrane系统评价员手册5.2中的工具评价文献质量后,采用Rev Man 5.3统计软件进行Meta分析。结果:共纳入6项RCT,合计527例患者。Meta分析结果显示,两组患者中央角膜厚度[MD=-13.63,95%CI(-28.50,1.23),P=0.07]、顶端角膜厚度[MD=-7.53,95%CI(-19.46,4.40),P=0.22]、最薄角膜厚度[MD=-5.87,95%CI(-17.69,5.95),P=0.33]、眼压[MD=-5.44,95%CI(-14.90,4.02),P=0.26]比较,差异均无统计学意义。结论:前列腺素类似物滴眼液对原发性开角型青光眼患者的角膜厚度无显著影响。
文摘The phenyl-substituted analog of prostaglandin F2α , latanoprost ( Xalatan; Pfizer, Inc, New York, NY) is an intraocular pressure (IOP)-lowering drug for use in patients with glaucoma and ocular hypertension. Latanoprost has been sho wn to stimulate eyelash hypertrichosis and has recently been proposed as a possi ble treatment for alopecia areata involving the eyelashes. We report a case of h ypertrichosis of the eyelashes caused by the prostamide bimatoprost (Lumigan; Al lergan, Inc, Irvine, Calif), a new IOP-lowering drug.
